Real-world evaluation of the efficacy and safety of disitamab vedotin (RC48) in urothelial carcinoma

RC48 showed encouraging activity and manageable safety in a real-world UC cohort. Prospective multicenter studies with longer follow-up are needed to validate these findings, compare monotherapy versus combination strategies, and define the optimal role of RC48 across UC disease stages.